MedTrace Logo

Study of OT202 in Treating Moderate to Severe Dry Eye

NCT06435182 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2024-05-30

No results posted yet for this study

Summary

This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.

Conditions

  • Dry Eye

Interventions

DRUG

OT202 conc 0.5%

Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily

DRUG

OT202 conc 0.1%

Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily

DRUG

Placebo

Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily

Sponsors & Collaborators

  • Ocumension Therapeutics (Shanghai) Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Wei Chen · Eye Hospital, WMU

  • Jialu Xia · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-10
Primary Completion
2024-01-26
Completion
2024-01-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435182 on ClinicalTrials.gov